Needles' Days Are Numbered - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Needles' Days Are Numbered
Private companies and universities are developing new ways to deliver protein drugs.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 14


Erik Greb
Patients who take biological drugs traditionally have had little choice but to submit to injections. Yet needlephobes should take heart. Several partnerships are developing other ways to deliver large molecules that seem to show promise.

Nanomedicine manufacturer Midatech Group (Oxford, England) and drug-delivery company MonoSol Rx (Warren, NJ) recently filed a provisional US patent application for Nanoparticle Film Delivery Systems that could transmit proteins and peptides through buccal or sublingual administration. The delivery system bypasses the gastrointestinal (GI) tract and sends medicine directly into the bloodstream. This mechanism could reduce side effects and prevent the GI tract from destroying the therapy.

More recently, the Georgia Institute of Technology gave Vyteris (Fair Lawn, NJ) the option to exclusively license its patented thermal-ablation and microdevice-fabrication technologies for transdermal drug delivery. The technology was developed to enhance skin permeation to the point where drugs with high molecular weight could be administered without injections or infusions.

These and other new technologies could one day challenge the dominance of injections as a method for administering vaccines. Considering how rapidly the market for vaccines is growing, drugmakers would do well to take notice of these exciting developments. Vaccinations might soon become as painless as freshening the breath with an oral strip. Maybe needles' days are numbered.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here